Vera Therapeutics, Inc. (NASDAQ:VERA) saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN Phase 3 trial data.
Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001) at week 36.
For other prespecified endpoints, atacicept treatment also demonstrated results that were consistent with or better than those previously observed in the ORIGIN Phase 2b trial.
The safety profile of atacicept in this analysis was favorable and comparable to that of the placebo.
Vera plans to share these results with the FDA in the coming weeks, and full results will be submitted to the American Society of Nephrology Kidney Week.
Vera is poised for potential commercial launch of atacicept in 2026, according to Marshall Fordyce, CEO of Vera Therapeutics.
Vera is currently not sharing estimated Glomerular Filtration Rate (eGFR) results.
The trial continues in a placebo-controlled, blinded manner to evaluate the change in kidney function over two years as measured by eGFR and is expected to be completed in 2027.
Price Action: VERA stock is up 58.9% at $30.33 during the premarket session at the last check on Monday.
You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.
In the case of Vera Therapeutics, which is trading at $18.95 as of publishing time, $100 would buy you 5.28 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource.
If your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
Read Next:
- GAP Flags Over $100 Million Tariff Burden Outside Guidance, Near-Term Stock Pressure Likely: Analyst
Image: Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
